| PERIOD ENDING | 31-Mar-01 | | Total Revenue | 167,973 | | Cost of Revenue | 154,863 | | | Gross Profit | 13,110 | | | Operating Expenses | | Research Development |
-
| | Selling General and Administrative | 23,630 | | Non Recurring |
-
| | Others |
-
| | | | Total Operating Expenses |
-
| | | | Operating Income or Loss | (10,520) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | (22,814) | | Earnings Before Interest And Taxes | (33,334) | | Interest Expense |
-
| | Income Before Tax | (33,334) | | Income Tax Expense |
-
| | Minority Interest |
-
| | | | Net Income From Continuing Ops | (33,334) | | | Non-recurring Events | | Discontinued Operations |
-
| | Extraordinary Items |
-
| | Effect Of Accounting Changes | 831 | | Other Items |
-
| | | | Net Income | (32,503) | | Preferred Stock And Other Adjustments |
-
| | | Net Income Applicable To Common Shares | ($32,503) |
|
0.51% Nasdaq 
Income Statement
